Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Simon G P Funnell; William E Dowling; César Muñoz-Fontela; Pierre-Stéphane Gsell; Donald E Ingber; Geraldine A Hamilton; Leen Delang; Joana Rocha-Pereira; Suzanne Kaptein; Kai H Dallmeier; Johan Neyts; Kyle Rosenke; Emmie de Wit; Heinz Feldmann; Pauline Maisonnasse; Roger Le Grand; Matthew B Frieman; Christopher M Coleman

doi:10.1038/s41467-020-17907-w

Journal articles

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Simon G P Funnell ^{1, *} William E Dowling ² César Muñoz-Fontela ³ Pierre-Stéphane Gsell ⁴ Donald E Ingber ⁵ Geraldine A Hamilton ⁶ Leen Delang ⁷ Joana Rocha-Pereira ⁷ Suzanne Kaptein ⁷ Kai H Dallmeier ⁷ Johan Neyts ⁷ Kyle Rosenke ⁸ Emmie de Wit ⁸ Heinz Feldmann ⁸ Pauline Maisonnasse ⁹ Roger Le Grand ⁹ Matthew B Frieman ¹⁰ Christopher M Coleman ¹¹

* Corresponding author

1 Public Health England [London]

2 CEPI - Coalition for Epidemic Preparedness Innovations [Washington, DC, États-Unis]

3 BNITM - Bernhard Nocht Institute for Tropical Medicine - Bernhard-Nocht-Institut für Tropenmedizin [Hamburg, Germany]

4 OMS / WHO - Organisation Mondiale de la Santé / World Health Organization Office

5 Harvard University [Cambridge]

6 Emulate, Inc. [Boston, MA, États-Unis]

7 KU Leuven - Catholic University of Leuven - Katholieke Universiteit Leuven

8 National Institute of Health [Hamilton, MT, États-Unis]

9 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes

10 University of Maryland School of Medicine

11 UON - University of Nottingham, UK

Abstract : There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Pharmaceutical sciences / Pharmacology

Life Sciences [q-bio] / Microbiology and Parasitology / Virology

Life Sciences [q-bio] / Human health and pathology / Emerging diseases

Complete list of metadata

Cited literature [13 references] Display Hide Download

https://www.hal.inserm.fr/inserm-02964247
Contributor : Myriam Bodescot Connect in order to contact the contributor
Submitted on : Monday, October 12, 2020 - 11:57:17 AM
Last modification on : Sunday, June 26, 2022 - 12:32:32 AM
Long-term archiving on: : Wednesday, January 13, 2021 - 6:42:08 PM

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

File

Identifiers

Collections

Citation

Export

Metrics

71

89

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

File

Identifiers

Collections

Citation

Export

Share

Metrics

71

89